IDYA
Price
$22.12
Change
-$0.03 (-0.14%)
Updated
Jul 17, 04:59 PM (EDT)
Capitalization
1.94B
26 days until earnings call
OCUL
Price
$11.40
Change
+$0.15 (+1.33%)
Updated
Jul 17, 04:59 PM (EDT)
Capitalization
1.79B
25 days until earnings call
Interact to see
Advertisement

IDYA vs OCUL

Header iconIDYA vs OCUL Comparison
Open Charts IDYA vs OCULBanner chart's image
IDEAYA Biosciences
Price$22.12
Change-$0.03 (-0.14%)
Volume$34.75K
Capitalization1.94B
Ocular Therapeutix
Price$11.40
Change+$0.15 (+1.33%)
Volume$32.36K
Capitalization1.79B
IDYA vs OCUL Comparison Chart in %
Loading...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IDYA vs. OCUL commentary
Jul 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a Hold and OCUL is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 18, 2025
Stock price -- (IDYA: $22.15 vs. OCUL: $11.25)
Brand notoriety: IDYA and OCUL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IDYA: 55% vs. OCUL: 89%
Market capitalization -- IDYA: $1.93B vs. OCUL: $1.81B
IDYA [@Biotechnology] is valued at $1.93B. OCUL’s [@Biotechnology] market capitalization is $1.81B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.62B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IDYA’s FA Score shows that 0 FA rating(s) are green whileOCUL’s FA Score has 0 green FA rating(s).

  • IDYA’s FA Score: 0 green, 5 red.
  • OCUL’s FA Score: 0 green, 5 red.
According to our system of comparison, OCUL is a better buy in the long-term than IDYA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IDYA’s TA Score shows that 3 TA indicator(s) are bullish while OCUL’s TA Score has 5 bullish TA indicator(s).

  • IDYA’s TA Score: 3 bullish, 5 bearish.
  • OCUL’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, OCUL is a better buy in the short-term than IDYA.

Price Growth

IDYA (@Biotechnology) experienced а -3.57% price change this week, while OCUL (@Biotechnology) price change was +4.55% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.06%. For the same industry, the average monthly price growth was +13.69%, and the average quarterly price growth was +40.92%.

Reported Earning Dates

IDYA is expected to report earnings on Nov 11, 2025.

OCUL is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+2.06% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IDYA($1.94B) has a higher market cap than OCUL($1.79B). OCUL YTD gains are higher at: 31.733 vs. IDYA (-13.813). OCUL has higher annual earnings (EBITDA): -176.35M vs. IDYA (-356.46M). IDYA has more cash in the bank: 693M vs. OCUL (350M). IDYA has less debt than OCUL: IDYA (26M) vs OCUL (76.2M). OCUL has higher revenues than IDYA: OCUL (59.6M) vs IDYA (7M).
IDYAOCULIDYA / OCUL
Capitalization1.94B1.79B108%
EBITDA-356.46M-176.35M202%
Gain YTD-13.81331.733-44%
P/E RatioN/AN/A-
Revenue7M59.6M12%
Total Cash693M350M198%
Total Debt26M76.2M34%
FUNDAMENTALS RATINGS
IDYA vs OCUL: Fundamental Ratings
IDYA
OCUL
OUTLOOK RATING
1..100
5922
VALUATION
overvalued / fair valued / undervalued
1..100
62
Fair valued
56
Fair valued
PROFIT vs RISK RATING
1..100
7888
SMR RATING
1..100
9497
PRICE GROWTH RATING
1..100
5838
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OCUL's Valuation (56) in the Pharmaceuticals Other industry is in the same range as IDYA (62) in the null industry. This means that OCUL’s stock grew similarly to IDYA’s over the last 12 months.

IDYA's Profit vs Risk Rating (78) in the null industry is in the same range as OCUL (88) in the Pharmaceuticals Other industry. This means that IDYA’s stock grew similarly to OCUL’s over the last 12 months.

IDYA's SMR Rating (94) in the null industry is in the same range as OCUL (97) in the Pharmaceuticals Other industry. This means that IDYA’s stock grew similarly to OCUL’s over the last 12 months.

OCUL's Price Growth Rating (38) in the Pharmaceuticals Other industry is in the same range as IDYA (58) in the null industry. This means that OCUL’s stock grew similarly to IDYA’s over the last 12 months.

OCUL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as IDYA (100) in the null industry. This means that OCUL’s stock grew similarly to IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IDYAOCUL
RSI
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 2 days ago
78%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
80%
Momentum
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bearish Trend 2 days ago
76%
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 9 days ago
77%
Bullish Trend 8 days ago
80%
Declines
ODDS (%)
Bearish Trend 7 days ago
77%
Bearish Trend 28 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
81%
Aroon
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
STPAX22.45N/A
N/A
Saratoga Technology & Comm A
OMGNX60.07N/A
N/A
Invesco Main Street R
PPQPX7.83N/A
N/A
Principal MidCap Growth III R5
MTCAX64.95N/A
N/A
MFS Technology A
TAVZX65.23N/A
N/A
Third Avenue Value Z

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with IMNM. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
+3.36%
IMNM - IDYA
60%
Loosely correlated
+15.12%
CGON - IDYA
60%
Loosely correlated
+4.53%
NRIX - IDYA
59%
Loosely correlated
+2.22%
CRNX - IDYA
59%
Loosely correlated
+0.22%
XENE - IDYA
58%
Loosely correlated
+0.44%
More

OCUL and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCUL has been loosely correlated with EYPT. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUL jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCUL
1D Price
Change %
OCUL100%
+1.44%
EYPT - OCUL
58%
Loosely correlated
+2.24%
IDYA - OCUL
56%
Loosely correlated
+3.36%
DNLI - OCUL
55%
Loosely correlated
+4.94%
RVMD - OCUL
55%
Loosely correlated
+1.56%
NRIX - OCUL
53%
Loosely correlated
+2.22%
More